Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological Disorders Angelini Ventures co-leads alongside Invivo Partners with participation from Innovestor’s Life Science Fund and other existing investors    Financing will support clinical development of Neumirna‘s...

Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing roundFinancing will enable Nouscom to continue advancing the clinical development of...